Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Change in Inventory (2017 - 2023)

Avalo Therapeutics (AVTX) has disclosed Change in Inventory for 7 consecutive years, with -$18000.0 as the latest value for Q3 2023.

  • For the quarter ending Q3 2023, Change in Inventory fell 1700.0% year-over-year to -$18000.0, compared with a TTM value of -$18000.0 through Jun 2024, down 260.0%, and an annual FY2023 reading of -$20000.0, down 11.11% over the prior year.
  • Change in Inventory was -$18000.0 for Q3 2023 at Avalo Therapeutics, down from -$1000.0 in the prior quarter.
  • Across five years, Change in Inventory topped out at $68294.0 in Q4 2019 and bottomed at -$411736.0 in Q2 2019.
  • Average Change in Inventory over 5 years is -$29155.1, with a median of -$3000.0 recorded in 2020.
  • The sharpest move saw Change in Inventory soared 600.0% in 2021, then plummeted 1700.0% in 2023.
  • Year by year, Change in Inventory stood at $68294.0 in 2019, then tumbled by 108.79% to -$6000.0 in 2020, then skyrocketed by 466.67% to $22000.0 in 2021, then crashed by 109.09% to -$2000.0 in 2022, then plummeted by 800.0% to -$18000.0 in 2023.
  • Business Quant data shows Change in Inventory for AVTX at -$18000.0 in Q3 2023, -$1000.0 in Q2 2023, and -$1000.0 in Q1 2023.